Cash from Financing (Quarterly) Chart

View Cash from Financing (Quarterly) for MKKGY.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Financing (Quarterly) Chart
Start Trial

Historical Cash from Financing (Quarterly) Data

View and export this data back to 2001. Start Trial.
Date Value
June 30, 2026 -920.17M
March 31, 2026 -72.54M
December 31, 2025 -232.81M
September 30, 2025 2.971B
June 30, 2025 -333.79M
March 31, 2025 -1.693B
December 31, 2024 -1.354B
September 30, 2024 787.26M
June 30, 2024 -388.31M
March 31, 2024 -116.13M
December 31, 2023 -1.035B
September 30, 2023 -330.50M
June 30, 2023 -627.19M
March 31, 2023 133.04M
December 31, 2022 -494.86M
September 30, 2022 -963.23M
June 30, 2022 191.27M
March 31, 2022 -353.38M
December 31, 2021 -348.08M
September 30, 2021 -1.345B
June 30, 2021 -1.276B
March 31, 2021 7.227M
December 31, 2020 -1.585B
September 30, 2020 -420.80M
June 30, 2020 -333.87M
Date Value
March 31, 2020 597.11M
December 31, 2019 -344.37M
September 30, 2019 1.059B
June 30, 2019 1.405B
March 31, 2019 -3.406M
December 31, 2018 -2.648B
September 30, 2018 -332.84M
June 30, 2018 -358.81M
March 31, 2018 -3.687M
December 31, 2017 -646.11M
September 30, 2017 -958.80M
June 30, 2017 -200.07M
March 31, 2017 -310.58M
December 31, 2016 -301.60M
September 30, 2016 -783.24M
June 30, 2016 -404.29M
March 31, 2016 -630.76M
December 31, 2015 3.195B
September 30, 2015 2.456B
June 30, 2015 -189.77M
March 31, 2015 2.535B
December 31, 2014 2.522B
September 30, 2014 -352.48M
June 30, 2014 -695.54M
March 31, 2014 9.722M

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
STRATEC SE -10.75M
Sartorius AG -340.21M
Petros Pharmaceuticals, Inc. 0.00
Danaher Corp. 7.273B
Illumina, Inc. -129.00M